MedPharm has announced a laboratory expansion following an internal investment of £1 million to increase its laboratory footprint in the UK by 60%. The expansion is to accommodate the new scientists needed to service the increase in demand for its formulation development, performance testing and manufacturing services. This increased capacity will allow MedPharm to extend its service offerings across these key areas of expertise.
“We are very pleased to announce this investment which reflects the trust an increasing number of clients are placing in our services”, said Dr. Andrew Muddle, MedPharm’s co-founder and Chief Executive Officer. “Our focus on the development topical and transdermal medicines which can benefit developers of new chemical entities, generics or OTC products alike is attracting ever increasing interest and this expansion will accommodate the demand for our services in the coming years”.